TD Cowen analyst Phil Nadeau reiterated a Buy rating on Neurocrine Bio. (NASDAQ: NBIX).The analyst commented: "We expect Crenessity's strong ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE